Found 120 clinical trials
PCSK9i in AAA123
Please see section 3 of the full protocol Please see section 3 of the full protocol Please see section 3 of the full protocol
- 0 views
- 18 Mar, 2025
- 1 location
ZEUS A research study to see how Ziltivekimab works compared to placebo in patients with cardiovascular disease, chronic kidney disease and inflammation (ZEUS)
The purpose of this study is to see if the new study drug, Ziltivekimab, can be used to treat people with cardiovascular disease, chronic kidney disease, and inflammation. The ZEUS study will see if Ziltivekimab can reduce the risk of having cardiovascular events (for example, heart attack and stroke). The …
- 0 views
- 03 May, 2025
- 1 location
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
Background Psoriasis causes chronic inflammation in the body. Researchers want to see if a kind of vitamin B3 dietary supplement can help. This might lead to more treatment options.
- 0 views
- 19 Feb, 2024
The Anti-inflammatory Effects of Hark ny Medicinal Water
The study aims to provide evidence on the effectiveness of Harkny medicinal water in psoriatic and rheumatoid arthritis patients using subjective and objective methods. It is a cross-over study, so first half of patients will receive medicinal water, the other half will receive tap water treatment, and after 6 months …
- 0 views
- 19 Feb, 2024
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions. The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug …
- 0 views
- 19 Feb, 2024
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
- 0 views
- 09 May, 2025
- 3 locations